RxDoctor Payments Data

Catherine Kroll, DO

Family Medicine · Gwinn, MINPI 1043260995

Payments from drug & device makers

$550in general payments, 2019–2025

Across 33 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$81
  • Sunovion Pharmaceuticals Inc.$77
  • Novo Nordisk$61
  • Amgen$60
  • Bayer$55
  • Lundbeck LLC$39
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$49590%
  • Education$5510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$550 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$787
Medicare patients
31
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban848$416,246
XareltoRivaroxaban281$125,233
JanuviaSitagliptin Phosphate173$110,091
Breo ElliptaFluticasone/Vilanterol152$77,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$60,619
TrulicityDulaglutide56$60,177
OzempicSemaglutide37$59,620
JardianceEmpagliflozin126$59,488
FarxigaDapagliflozin Propanediol66$48,835
AptiomEslicarbazepine Acetate23$40,674
EntrestoSacubitril/Valsartan48$38,160
Lantus SolostarInsulin Glargine,hum.Rec.Anlog339$27,486
LinzessLinaclotide48$26,752
Potassium Chloride591$23,486
Invega SustennaPaliperidone Palmitate13$22,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$416,246848 claims
Johnson & JohnsonXarelto, Invega Sustenna$31$147,291294 claims
MerckJanuvia, Lagevrio (Eua)$15$124,971195 claims
Lilly USA, LLCTrulicity, Mounjaro$16$82,12177 claims
Novo NordiskOzempic$61$59,62037 claims
AstraZenecaFarxiga, Breztri Aerosphere$18$58,79378 claims
Sunovion Pharmaceuticals Inc.Aptiom$77$40,67423 claims
AbbVieLinzess$81$26,75248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Gwinn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →